M1 Muscarinic Agonists Target Major Hallmarks of Alzheimer's Disease -an Update

By  

Current Alzheimer Research, Vol. 4, Iss. 5, 2007-12 ,pp. : 577-580

Bentham Science Publishers

Access to resources Recommend Favorite

M₁ muscarinic agonists can modulate some of the hallmarks in Alzheimer’s disease: Implications in future therapy

By Fisher Abraham   Pittel Zipora   Haring Rachel   Bar-Ner Nira   Kliger-Spatz Michal   Natan Niva   Egozi Inbal   Sonego Hagar   Marcovitch Itzhak   Brandeis Rachel  

Journal of Molecular Neuroscience, Vol. 20, Iss. 3, 2003-08 ,pp. : 349-356

Humana Press, Inc

Access to resources Recommend Favorite

Reduced High-Affinity Agonist Binding at the M 1 Muscarinic Receptor in Alzheimer's Disease Brain: Differential Sensitivity to Agonists and Divalent Cations

By Ladner C.J.   Lee J.M.  

Experimental Neurology, Vol. 158, Iss. 2, 1999-08 ,pp. : 451-458

Elsevier

Access to resources Recommend Favorite

Perispinal Etanercept for Treatment of Alzheimer's Disease

By  

Current Alzheimer Research, Vol. 4, Iss. 5, 2007-01 ,pp. : 550-552

Bentham Science Publishers

Access to resources Recommend Favorite

Alzheimer's Disease: Pharmacological Treatment and Management

By Rivas-Vazquez Rafael A.   Carrazana Enrique J.   Rey Gustavo J.   Blais Mark A.   Racher David A.  

The Clinical Neuropsychologist (Neuropsychology, Development and Cognition: Sec, Vol. 14, Iss. 1, 2000-02 ,pp. : 93-109

Routledge Ltd

Access to resources Recommend Favorite